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 Abstract 
 Background: Small vessel disease (SVD) represents a common often progressive condition in 
elderly people contributing to cognitive disability. The relationship between cerebrospinal 
fluid (CSF) biomarkers and imaging correlates of SVD was investigated, and the findings were 
hypothesized to be associated with a neuropsychological profile of SVD.  Methods: CSF SVD-
related biomarkers [neurofilament light (NF-L), myelin basic protein (MBP), soluble amyloid 
precursor protein-β (sAPPβ), matrix metalloproteinases (MMPs), and tissue inhibitor of metal-
loproteinase (TIMP)] were analysed in 46 non-demented elderly with imaging findings of SVD. 
We assessed the relationship between the CSF biomarkers and white matter hyperintensity 
(WMH) volume, diffusion-weighted imaging and atrophy as well as their association with neu-
ropsychological profiles.  Results: The WMH volume correlated with ventricular dilation, which 
was associated with executive function and speed and attention. Increased WMH and ven-
tricular dilation were related to increased CSF levels of TIMP-1, NF-L and MBP and to de-
creased sAPPβ. A positive correlation was found between the CSF biomarker MMP-9 and 
WMH progression.  Conclusions: The link between progressive WMH and MMP-9 suggests 
an involvement of the enzyme in white matter degeneration. CSF TIMP-1, NF-L, MBP and 
sAPPβ may function as biological markers of white matter damage.  © 2014 S. Karger AG, Basel 
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 Introduction 
 White matter disease caused by arteriolosclerotic lesions of the small penetrating 
arteries of the brain, in this context denominated ‘small vessel disease’ (SVD), represents a 
common and often progressive condition in elderly people. It has been found to give rise to 
various degrees of cognitive impairment and, in its pronounced form, it is known as subcor-
tical ischemic vascular dementia (SIVD)  [1] . The neuropsychological profile associated with 
SIVD differs from that of Alzheimer’s disease (AD) with deficits in the executive functions 
and speed and attention domains  [2] . The biochemical marker deviations and the refined 
magnetic resonance imaging (MRI) changes for these specific cognitive alterations are less 
well defined.
 White matter hyperintensities (WMHs) visualized by MRI have, to a modest degree, 
been correlated with cognitive dysfunction  [3]. Also, it is possible to have WMH without any 
sign of dysfunction, which might be explained by the type of damaged tissue and the extent 
of damage  [4] . It is not fully understood how severe a demyelinating process must be before 
the neuronal function is compromised or cognitive dysfunction evolves. One way to address 
these questions is through the combination of biomarkers and neuropsychological evalu-
ation. Imaging tools that allow for the assessment of white matter structural integrity, such 
as diffusion-weighted imaging (DWI), seem to be promising. The mean diffusivity, or the 
apparent diffusion coefficient (ADC), of tissue water depends on the structural integrity at a 
cellular and subcellular level  [5] . Therefore, an increase in tissue water diffusivity is asso-
ciated with a loss of tissue or cellular architecture for instance affected by a pathological 
process such as SVD. To compare the structural changes seen by conventional MRI, such as 
WMH volumetric and atrophic changes, with DWI of WMH and normal-appearing brain 
tissue (NABT) of the white and the gray matter and biomarkers could provide for a deeper 
molecular understanding. Cerebrospinal fluid (CSF) biomarkers reflecting SVD disease 
processes such as blood brain barrier disruption [matrix metalloproteinases (MMPs) and 
tissue inhibitors of metalloproteinases (TIMPs)] and white matter lesions [MMPs, neurofil-
ament light (NF-L), myelin basic protein (MBP), and soluble amyloid precursor protein 
(sAPP)] might mirror early alterations in tissue damage, and thus, might be useful as markers 
in CSF. The neuropathological findings of amyloid plaques and neurofibrillary tangles found 
in the gray matter in pure AD and in patients with mixed cerebrovascular disease/AD (MIX) 
are associated with established AD biomarkers [total tau (T-tau), amyloid-β 1–42 (Aβ 1–42 ) and 
phosphorylated tau (P-tau 181 )]  [6–8] and might be used interchangeably with NABT ADC 
measurements for early disease detection. The baseline levels of the above CSF biomarkers 
were hypothesized to be associated with changes in the white and the gray matter, respec-
tively, as assessed by MRI. Dysfunctions in speed and attention and executive functions were 
hypothesized to be associated with both the SVD biomarker profile and MRI changes of the 
white matter.
 Material and Methods 
 Participants 
 This single-centre substudy of the LADIS (Leukoaraiosis and Disability in the Elderly) 
project included 46 individuals (22 women and 24 men; age 74 ± 5 years) ( table 1 ) and is a 
continuation of a previous substudy of the LADIS project  [9] . LADIS is a European longitudinal 
multi-centre study with the aim to investigate white matter lesion as an independent predictor 
of the transition to disability  [10] . The inclusion criteria were: (a) age between 65 and 84 
years; (b) hyperintensities of cerebral subcortical white matter on MRI, from mild to severe, 
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according to the categorization of the Fazekas scale  [11] ; (c) no or mild disability as assessed 
by the Instrumental Activities of Daily Living scale  [12] , and (d) presence of a contactable 
informant. Exclusion criteria were: (a) subjects prone to dropout because of severe illnesses 
(cardiac, hepatic or renal failure, neoplastic or other relevant systemic disease); (b) severe 
unrelated neurological diseases; (c) leukoencephalopathies of non-vascular origin (immuno-
logic-demyelinating, metabolic, infectious) revealed by brain imaging; (e) severe psychiatric 
disorders; (f) inability to give informed consent, and (g) inability or refusal to undergo cranial 
MRI scanning. All subjects underwent clinical examination including anamnesis and func-
tional tests, such as global functioning, cognitive, motor, psychiatric, and quality-of-life 
measures. The study was approved by the Ethics Committee at the University of Gothenburg 
and was conducted in accordance with the Helsinki Declaration. All subjects gave their 
informed consent to participate in the study.
 Neuropsychological Assessment 
 The neuropsychological test battery consisted of parts of the LADIS battery  [13] with 
tests of speed and attention, episodic memory and executive functions. Speed and attention 
was assessed by the Trail Making Test A and B  [14] , the Symbol Digit Modalities Test and digit 
cancellation, whereas episodic memory was assessed by the word recall subtest from the 
Vascular Dementia Assessment Scale cognitive subscale  [13] since the California Verbal 
Learning Test (CVLT)  [15] , which was used at the 3-year follow-up appointment, was not 
available at baseline. Executive functions were evaluated by the Stroop Colour Word Test 
(Victoria version)  [16] , verbal fluency (animal names generated in 1 min), a maze task, the 
backward digit span task  [17] and subtraction scores from the Trail Making Test (B time – A 
time). Each test score was z-transformed in order to construct composite scores for each 
domain expressing the general level of performance within that domain. The sum of the 
z-scores of learning trials 1–5, delayed recall and recognition on CVLT were used for the 
episodic memory composite z-score. The z-scores of neuropsychological tests, where a higher 
score represented poorer performance, were inverted (–z) for the calculation of composite 
scores.
 Biochemical Analyses 
 At baseline, patients were subjected to lumbar puncture through the L3/L4 interspace in 
the morning to avoid diurnal fluctuations in biomarker levels. CSF was collected in polypro-
 Table 1.  Demography of patient material at baseline and at follow-up
Baseline (n = 46) Follow-up (n = 34)
Age , years 74 ± 5 73 ± 5
Female/male 22/24 15/19 
MMSE 28.4 ± 1.9 28.9 ± 1.3
WMH volume, mm3 24 ± 18 22 ± 17
Ventricular dilation 4.3 ± 1.8 4.1 ± 1.8
Sulcal atrophy 4.41 ± 1.4 4.4 ± 1.5
NABT ADC 1,329 ± 122 1,312 ± 136
NABT rPHa 0.01 ± 0.001 0.01 ± 0.001
Fazekas score 2.0 ± 0.8 2.0 ± 0.8
 Data are means ± standard deviations. MMSE = Mini-Mental State Examination.
a The relative peak height reflects the number of voxels in normal-appearing white matter in relation to 
the total number of voxels contributing to the histogram. 
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pylene tubes and submitted to centrifugation at 2,000  g at room temperature for 10 min. The 
supernatant was aliquoted into screw-cap polypropylene tubes and stored at –80 ° C pending 
biochemical analyses. The CSF levels of T-tau, P-tau 181 and Aβ 1–42 were assessed by Luminex ® 
xMAP ® technology (INNO-BIA AlzBio3; Innogenetics, Gent, Belgium)  [18] . NF-L was analysed 
by ELISA (NF-light ® ; UmanDiagnostics, Umeå, Sweden)  [19] as was MBP (Active ® MBP; Diag-
nostic Systems Laboratories Inc., Webster, Tex., USA). The MMPs (MMP-1, MMP-2, MMP-3, 
MMP-9 and MMP-10) were assessed by multiplex (MSD ® Multi-Spot ® ) and TIMP-1 by 
singleplex electrochemiluminescent ELISAs (MSD Multi-Array ® ; Meso Scale Discovery, Gai-
thersburg, Md., USA). Intra-assay coefficients of variation were <10% for all assays, except 
for the MMP assays which were <15%.
 Magnetic Resonance Imaging 
 MRI assessments were performed at the Sahlgrenska University Hospital, Gothenburg, 
Sweden, according to a standardized protocol (LADIS) in which a 1.5-tesla scanner was used 
to assess T1-weighted 3-dimensional magnetization-prepared rapid-acquisition gradient 
echo (coronal and sagittal plane), T2-weighted fast-spin echo (axial plane) and fluid-atten-
uated inversion recovery (FLAIR; axial plane) sequences. All scans were collected centrally, 
and the WMH ratings were performed on FLAIR images. The Fazekas  [11] and Scheltens  [20] 
scales were used for visual staging of the WMH, and quantitative assessments were done 
with a semiautomated volumetric technique  [21] performed on the same sequences, 
including the infratentorial region. The progression of WMH was evaluated at follow-up with 
the extended Rotterdam Progression Scale  [22] . Lacunes were identified by number through 
a combination of FLAIR, MP-RAGE (magnetization-prepared rapid-gradient echo) and T2 
images  [23] .
 DWI was performed on the 1.5-tesla whole-body system with a pulsed-gradient spin-
echo sequence with an echo planar imaging readout with 2 b factors (b = 0 s/mm 2 and b = 
900–1,000 s/mm 2 ). The diffusion gradients were applied along the three principal directions, 
and the voxel size was 1.95 × 1.95 × 1.95 mm. The DWI metrics included the average ADC, or 
mean diffusivity, of both WMH and NABT of the white and the gray matter. The relative peak 
height (rPH) and peak position (PP) of NABT were determined by histogram analysis. Further 
details are found elsewhere  [24] .
 Ventricular dilation and sulcal atrophy were evaluated at the Department of Neurology 
at the Medical University of Graz by one rater. A rating scale previously assessed in other 
studies  [25, 26] ranging from 1 (no atrophy) to 8 (severe atrophy) was employed. All MRI 
measurements evaluated in this study were baseline values except for the progression of 
WMH.
 Statistical Analysis 
 The demographic, clinical and CSF data are presented as mean values and standard devi-
ations. Univariate pairwise comparison was assessed by the Mann-Whitney U test for 
continuous variables between groups, and the non-parametric χ 2 test was used for dichot-
omous variables. Correlation analyses between MRI alterations and biomarker levels were 
performed using Spearman’s rank correlation; the values are presented by Spearman’s rank 
correlation coefficient (ρ). Associations between continuous baseline MRI variables and 
neuropsychological profiles assessed both at baseline and at 3-year follow-up were evaluated 
by linear regression. The patients displayed a large variability in cognitive impairment at 
baseline; thus, analyses of change over time, i.e. Δ (follow-up – baseline data), were not 
performed. All statistical analyses were performed with PASW statistics 18 (SPSS Inc., Chicago, 
Ill., USA).
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 Results 
 CSF measurements were performed on 46 patients of whom 44 underwent DWI assess-
ments. Correlation analyses were performed between baseline biomarker levels and baseline 
MRI assessments to evaluate the biomarker relationship with specific tissue damage. The 
WMH volume, Scheltens total and ventricular dilation correlated with TIMP-1, NF-L and 
sAPPβ, while TIMP-1, NF-L and MBP correlated with WMH ADC ( table 2 ). Ventricular dilation 
in turn correlated with WMH ADC (ρ = 0.363; p = 0.018), WMH volume (ρ = 0.466; p = 0.001) 
and Scheltens total (ρ = 0.337; p = 0.022). Furthermore, P-tau and MMP-10 correlated with 
NABT ADC and PP, while P-tau and MMP-3 correlated with sulcal atrophy ( table 2 ). Moreover, 
NABT ADC, NABT rPH and NABT PP all highly correlated with sulcal atrophy (ρ = 0.699, p < 
 Table 2. Correlation between baseline CSF biomarker levels and baseline MRI variables
WMH
volume
Scheltens
total
WMH
ADC
NABT
ADC
NABT
PP
Sulcal
atrophy
Ventricle
dilation
Rdam
ext.
P-tau
ρ 0.366 0.317 0.290
Sig. n.s. n.s. n.s. 0.015 0.036 0.045 n.s. n.s.
n  44 44 46
MMP-10
ρ 0.432 0.306
Sig. n.s. n.s. n.s. 0.003 0.043 n.s. n.s. n.s.
n 44 44
MMP-3
ρ 0.348
Sig. n.s. n.s. n.s. n.s. n.s. 0.018 n.s. n.s.
n 46
MMP-1
ρ 0.326
Sig. n.s. n.s. n.s. 0.035 n.s. n.s. n.s. n.s.
n 44
TIMP-1
ρ 0.428 0.525 0.437 0.405
Sig. 0.004 <0.001 0.002 n.s. n.s. n.s. 0.005 n.s.
n 43 45 46 46
NF-L
ρ 0.368 0.568 0.467 0.375 0.305
Sig. 0.016 <0.001 0.001 n.s. 0.014 n.s. 0.039 n.s.
n 42 44 46 42 46
MBP
ρ 0.323 0.296 0.358
Sig. n.s. 0.032 0.048 n.s. 0.021 n.s. n.s. n.s.
n 44 45  41  
sAPPβ
ρ –0.332 –0.342 –0.451
Sig. 0.027 0.023 n.s. n.s. n.s. n.s. 0.002 n.s.
n 42 44 45
MMP-9
ρ 0.362
Sig. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.028
n 37
Rdam ext. = Rotterdam extended; Sig. = significance; n.s. = not significant.
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0.001; ρ = –0.422, p = 0.005; ρ = 0.570, p < 0.001, respectively). The NABT metrics and sulcal 
atrophy did not correlate with any of the WMH measurements or ventricular dilation. The only 
CSF biomarker correlating with the progression of white matter changes was MMP-9 ( table 2 ). 
The albumin ratio correlated with the concentration of TIMP-1 (ρ = 0.327; p = 0.028), but no 
correlation was found between the albumin ratio and any of the imaging variables.
 Ventricular dilation, NABT ADC, NABT rPH and NABT PP were the only MRI variables 
found to be associated with the neuropsychological profiles. The relationship between these 
changes and CSF biomarkers was further investigated.
 The continuous baseline MRI variables were assessed against continuous composite 
z-scores of the cognitive domains of memory, speed and attention and executive function in 
order to investigate which modalities were related ( table 3 ). Increased ventricular dilation 
was associated with worse memory performance in the total material at baseline (n = 46), but 
also with worse speed and attention and poorer executive function together with increased 
NABT ADC and decreased NABT rPH. Furthermore, increased NABT PP was associated with 
a decrease in speed and attention. The CSF markers Aβ 1–42 , P-tau and MMP-10 were the only 
fluid biomarkers (including albumin ratio) that were associated with cognitive profiles, i.e. 
memory function (p = 0.007, p = 0.041 and p = 0.040, respectively) and speed and attention 
(p = 0.001, p = 0.014 and p = 0.051, respectively), at baseline.
 A subpopulation of patients (n = 34) was assessed to verify if the same baseline biomarker 
changes were important for the cognitive profile at follow-up. The subpopulation was based 
on the availability of CSF, MRI and neuropsychological baseline and follow-up variables and 
did not significantly differ from the total patient population ( table 1 ). However, when assessing 
the baseline neuropsychological functions of the 12 patients who were excluded due to 
missing neuropsychological evaluation at follow-up, memory function was significantly 
worse (p = 0.021) compared to the 34 patients in the subpopulation. The other functions did 
 Table 3. Association between ventricular dilation and NABT alterations at baseline and neuropsychological 
functions at baseline and follow-up
Baseline (n = 46)  Follow-up (n = 34)
Ventricular
dilation
NABT
rPH1
NABT
ADC2
NABT
PP3
Ventr icular
dilation
NABT
rPH
NABT
ADC
NABT
PP
Memory function
β
SE
p
–0.36
0.12
0.013 0.261 0.483 0.684 0.070 0.463 0.546 0.933
Speed and attention
β
SE
p
–0.35
0.13
0.019
0.48
0.13
0.001
–0.35
0.14
0.024
–0.39
0.14
0.010
–0.39
0.18
0.023 0.051 0.111 0.085
Executive function
β
SE
p
–0.32
0.10
0.031
0.49
0.09
0.001
–0.33
0.10
0.033 0.109
–0.45
0.11
0.008 0.114 0.121 0.527
The β value and SE are only shown for significant measures.
1 rPH: lower values indicate less tissue with normal diffusivity in the analysed tissue compartment.
2 ADC: higher values indicate higher diffusivity in the analysed tissue compartment.
3 PP: a shift towards higher values indicates a global increase in diffusivity in the analysed tissue 
compartment.
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not significantly differ between the groups. Ventricular dilation at baseline was associated 
with speed and attention and executive function at follow-up. Both Aβ 1–42 and MMP-10 were 
associated with memory function (p = 0.012 and p = 0.040, respectively), while only Aβ 1–42 
was associated with speed and attention (p = 0.027) at follow-up. There was also a trend 
towards an association between TIMP-1 and albumin ratio when looking at speed and 
attention (p = 0.070 and p = 0.073, respectively).
 Discussion 
 The main finding was that WMH and ventricular dilation were related to altered baseline 
CSF levels of TIMP-1, NF-L, MBP and sAPPβ, which have previously been reported to be 
changed in patients with SIVD and MIX  [9, 27, 28] . In addition, an association between baseline 
WMH volume and ventricular dilation, which in turn was associated with both baseline and 
follow-up executive function and speed and attention, was found.
 At baseline, ventricular dilation was associated with worse performance in all cognitive 
domains. However, WMH was only indirectly related to cognitive functions through the corre-
lation with ventricular dilation and changes in CSF sAPPβ, NF-L and TIMP-1 levels. It has 
previously been shown in several LADIS studies that the WMH volume is directly associated 
with poor longitudinal cognitive function  [29] , particularly with deterioration in psycho-
motor speed and executive functions  [30] ; it is likely that the disconnection in this substudy 
is due to the small sample size. Nevertheless, the WMH volume might be more subtle and 
ventricular dilation might capture early cell and tissue alterations that ultimately affect 
cognitive functions, and thus, might be an earlier marker of cognitive decline. The biomarkers 
seem to capture the WMH volume as well as total loss of brain tissue, which would reflect the 
overall function of the MMP/TIMP system and white matter-specific alterations such as 
axonal destruction reflected by NF-L, MBP and sAPPβ. The reduction in sAPPβ could also be 
due to decreased shedding regulated by the MMP system. Furthermore, the correlation 
between ventricular dilation and WMH volume and their relationship to the CSF biomarkers 
TIMP-1, sAPPβ and NF-L imply the importance of these changes to SVD and disability since it 
has previously been shown that MIX and SIVD patients share a changed CSF profile of the 
biomarkers TIMP-1, MBP, NF-L and Aβ 1–42  [27, 31] .
 Deterioration in executive functions and speed and attention is found in patients with 
SVD, which in this study population could relate to both SIVD and MIX. Therefore, it was 
intriguing to find a relationship between executive function and speed and attention at 
baseline and NABT metrics, since NABT ADC was also associated with the CSF markers 
P-tau 181 and MMP-10. Both these CSF markers are found at increased levels in MIX patients 
 [27, 32] . Furthermore, there was a direct association between Aβ 1–42 , P-tau and MMP-10 and 
cognitive dysfunction (memory function, speed and attention) at baseline, while Aβ 1–42 
(memory function, speed and attention) and MMP-10 (memory function) were associated 
with cognitive functions at follow-up. Alterations in P-tau, Aβ 1–42 and MMP-10 levels are 
found in patients who primarily suffer from memory deficits, i.e. AD as well as MIX  [27, 32] , 
while Aβ 1–42 and MMP-10 are also altered in SIVD patients  [27] with deficits in executive func-
tions and speed and attention  [2] . Speed and attention and executive functions remained 
significantly associated with ventricular dilation at follow-up, while neither NABT nor P-tau 
was associated with any functional domain. The patients who dropped out after baseline 
assessments performed significantly worse only on memory tasks compared to the popu-
lation that was assessed at follow-up. Thus, the loss of association for P-tau at follow-up might 
be due to the drop in patients suffering mainly from memory deficits with known neuro-
pathological findings of neurofibrillary tangles in the hippocampus and the entorhinal cortex 
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 [33] . Furthermore, NABT metrics may be more often attributed to the disintegration of gray 
matter neurons and neuritis than to the white matter, which could explain the loss of asso-
ciation with cognitive dysfunction when patients with more severe gray matter alterations 
dropped out. This would also in turn explain why there were no associations between NABT 
measures and CSF biomarkers that have previously been shown to be altered in patients with 
pure SIVD (TIMP-1, NF-L, MBP and sAPP)  [27] .
 In addition, MMP-9 was the only biochemical marker that was connected to progressive 
white matter lesions, and it has previously been shown to be elevated in MIX and SIVD patients 
as well as after stroke  [27, 34] . The fact that MMP-9 has been related to the development of 
intracerebral haemorrhage  [35] and been shown to be continuously elevated in patients with 
stroke progression and larger infarct volumes in the subacute phase  [36] is possibly supporting 
a detrimental role of MMP-9. The potential role of MMP-9 as an early progression marker in 
CSF for white matter lesions, but also as a (SIVD) disease prognostic marker, needs to be 
further evaluated.
 All CSF and MRI biomarkers were analysed at baseline in patients with no or only mild 
cognitive impairment, and the fact that the SIVD CSF markers seem to reflect biological 
changes in the white matter, as detected by MRI, at this early stage makes them even more 
interesting in terms of possible early diagnostic tools. However, studies with larger samples 
are warranted to elucidate the relationship between the structural and biomarker changes 
and to confirm the findings. The disconnection between the neuropsychological profiles and 
alterations in single CSF biomarkers will have to be further assessed. It is likely that a combi-
nation of CSF biomarkers might better reflect deficits in different cognitive domains and this 
is why some of the imaging variables seem to be more often related to cognitive deterioration 
than CSF variables. It is also possible that specific combinations of CSF biomarkers or more 
sensitive imaging tools, such as diffusion tensor imaging, could improve the recognition of 
more specific cognitive functions. All in all, the alterations in cognitive domains related to 
SIVD together with changes in CSF biomarkers reflecting the biological processes of the 
disease seem to be offering unique, but related, information that could contribute to an early 
diagnosis. It will also be important to determine the predictive value and the specificity of 
ventricular dilation for the development of cognitive dysfunctions that relate to AD and SIVD.
 In conclusion, the intricate relationship between alterations in the biomarker levels of 
NF-L, MBP, MMP-9, TIMP-1 and sAPPβ and imaging changes in both WMH and ventricular 
dilation together with domain-specific alterations in neuropsychological functions point to a 
combined usefulness of these modalities as early diagnostic markers to reflect SVD patho-
logical processes.
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